Valoración del impacto del pH urinario en la elección de los antibióticos. Una revisión sistemática / Urinary pH and antibiotics, choose carefully. a systematic review

La infección urinaria no complicada es la infección bacteriana más frecuente en las mujeres. Desde 1948 se conoce la relación entre el pH urinario y los antibióticos. Nos propusimos buscar el pH urinario más apropiado para cada familia de antibióticos y evaluar si el pH modifica la sensibilidad bacteriana frente a estos. Se incluyeron ensayos in vitro y estudios in vivo que incluían una o más especies bacterianas y se analizó el efecto de uno o más antibióticos a diferentes valores de pH. También se incluyeron ensayos clínicos controlados aleatorizados en infección urinaria no complicada (con la definición de las directrices de la EAU de 2019), eligiendo los antibióticos en función del pH urinario o utilizando un antibiótico con modificadores del pH urinario (L-metionina, vitamina C, etc.) frente a un antibiótico y un placebo. Se utilizó la herramienta Quadas-2 para evaluar la calidad de los estudios y el conjunto de ítems comprendidos en la declaración PRISMA para las revisiones sistemáticas. Dos autores revisaron y evaluaron los trabajos de forma independiente, y otros dos autores repitieron la búsqueda individualmente. Un quinto investigador actuó como árbitro, y otro autor colaboró como consultor farmacéutico hospitalario. Los antibióticos cuya actividad es favorecida en medios alcalinos son la mayoría de las fluoroquinolonas, los aminoglucósidos y la trimetoprima. Los antibióticos cuya actividad es favorecida en medios ácidos son la fosfomicina, la tetraciclina, la nitrofurantoína y algunos β-lactámicos. Se sugiere realizar urocultivos con antibiograma, tanto en medios ácidos como alcalinos, para definir el perfil de susceptibilidad antimicrobiana. No hay pruebas suficientes de estudios in vivo que respalden la elección de un antibiótico en función del pH urinario del paciente o el uso de modificadores del pH urinario para obtener tasas más altas de curación (AU)

Uncomplicated urinary tract infection (UTI) is the most common bacterial infection in women. Since 1948, the relationship between urinary pH and antibiotics has been established. We aimed to search for the best urinary pH for each family of antibiotics and to assess whether pH changes bacterial susceptibility to them. We included in vitro research and in vivo studies including one or more bacterial species and tested the effect of one or more antibiotics at different pH values. We also included randomized controlled clinical trials in uncomplicated UTI (EAU guidelines 2019 definition), choosing the antibiotics based on urinary pH or using an antibiotic plus urinary pH modifiers (L-methionine, vitamin C...) vs an antibiotic and a placebo. Quadas-2 tool was used as a quality assessment of the studies and PRISMA set of items for systematic reviews. Two authors independently screened and evaluated the papers, while two additional authors individually repeated the search. A fifth researcher acted as an arbiter, and another author collaborated as a hospital pharmaceutical consultant. Alkaline-friendly antibiotics are most fluoroquinolones, aminoglycosides, trimethoprim. Acidic-friendly antibiotics are fosfomycin, tetracycline, nitrofurantoin and some β-lactams. We suggest performing urine cultures with antibiogram tests, in both acidic and alkaline media, to define the bacterial susceptibility profile. There is insufficient in vivo evidence to support whether choosing an antibiotic based on a patient's urinary pH or adding urinary pH modifiers will lead to a higher cure rate (AU)

Urinary pH and antibiotics, choose carefully. A systematic review.

Uncomplicated urinary tract infection (UTI) is the most common bacterial infection in women. Since 1948, the relationship between urinary pH and antibiotics (ABs) has been established. We aimed to search for the best urinary pH for each family of antibiotics and to assess whether pH changes bacterial susceptibility to them. We included in vitro research and in vivo studies including one or more bacterial species and tested the effect of one or more ABs at different pH values. We also included randomized controlled clinical trials (RCTs) in uncomplicated UTI (EAU guidelines 2019 definition), choosing the ABs based on urinary pH or using an antibiotic plus urinary pH modifiers (L-methionine, vitamin C…) vs. an antibiotic and a placebo. Quadas-2 tool was used as a quality assessment of the studies and PRISMA set of items for systematic reviews. Two authors independently screened and evaluated the papers, while two additional authors individually repeated the search. A fifth researcher acted as an arbiter, and another author collaborated as a hospital pharmaceutical consultant. Alkaline-friendly antibiotics are most fluoroquinolones, aminoglycosides, trimethoprim. Acidic-friendly antibiotics are fosfomycin, tetracycline, nitrofurantoin and some ß-lactams. We suggest performing urine cultures with antibiogram tests, in both acidic and alkaline media, to define the bacterial susceptibility profile. There is insufficient in vivo evidence to support whether choosing an antibiotic based on a patient's urinary pH or adding urinary pH modifiers will lead to a higher cure rate.

El sexismo en las y los profesionales de salud mental: un factor de riesgo psicosocial para la detección de la desigualdad de género / Sexism in Mental Health Professionals: A Social Psychological Risk Factor for Detecting Gender Inequality

Diversos organismos recomiendan a las y los profesionales de salud superar las propias creencias sexistas y apuntan a la importancia de abordar la desigualdad de género. En este sentido, este trabajo se centra en: (1) conocer los niveles de sexismo ambivalente en profesionales de salud mental, (2) analizar la asociación entre sexismo y características sociodemográficas y de perspectiva de género y (3) estudiar la asociación entre sexismo y detección de desigualdad de género en consulta. 449 profesionales de salud mental completaron la Escala de Sexismo Ambivalente, así como otro cuestionario desarrollado ad-hoc. Se realizaron análisis no paramétricos. Los datos mostraron, entre otros aspectos, un nivel bajo de sexismo en la muestra, así como que las y los profesionales que manifestaron niveles significativamente más bajos de sexismo, detectaron más problemas de desigualdad en consulta. Los resultados subrayan la importancia de reducir el sexismo de las y los profesionales para identificar los problemas de desigualdad de género (AU)

Some organizations recommend that healthcare professionals overcome their own sexist beliefs and emphasize the importance of dealing with gender inequality. Thus, this study focused on: (1) find out the levels of ambivalent sexism in a network of mental health professionals in Spain, (2) analyze the association between sexism, sociodemographic cha-racteristics and gender perspective, and (3) study the association between sexism and gender inequality detection during clinical attention. The sample was comprised of 449 mental health professionals who filled in the Ambivalent Sexism Inventory and another ad hoc questionnaire developed. Variables were compared by nonparametric analysis. The data showed low levels of sexism in the sample, and that the professionals who obtained lower levels of sexism found more problems related to gender inequality during clinical attention. The results underline the importance of intervention for reducing sexism of professionals in order to contribute to a more unbiased detection of problems of gender inequality (AU)

Aplicación de la metodología Lean healthcare en un servicio de urología de un hospital terciario como herramienta de mejora de la eficiencia / Application of Lean Healthcare methodology in a urology department of a tertiary hospital as a tool for improving efficiency

Objetivo: Descripción de la aplicación de la metodología Lean como método de mejora continua de la eficiencia en un servicio de urología de un hospital terciario. Material y métodos: La aplicación de la metodología Lean healthcare en un servicio de urología se realizó en 3 fases: 1) formación de equipo y mejora del feedback entre los profesionales; 2) gestión por procesos y súper-especialización; y 3) mejora de indicadores (mejora continua). La obtención de los indicadores se realizó a partir de los sistemas de información del hospital. La principal fuente de información fue el Cuadro integral de dirección de sistemas sanitarios. La comparación con otros servicios de urología autonómicos o nacionales se realizó a través de la misma plataforma, con la ayuda del servicio de documentación del hospital (IASIST). Se estableció una línea de base con los indicadores obtenidos en el año 2011 para el análisis comparativo de los resultados tras la implantación de la metodología Lean healthcare. Resultados: La aplicación de esta metodología se tradujo en una alta satisfacción de los profesionales, una mejora de los indicadores de calidad alcanzando en 4 años un ICAR de 0,59 y un IMAR de 0,24. En el indicador de eficiencia IEAR se alcanzó un valor de 0,61, con un ahorro de 2.869 estancias frente al Benchmarking nacional (IASIST). El IRAR fue el único indicador por encima del estándar, con un valor de 1,36, pero con una mejora evolutiva anual del mismo. Conclusiones: La metodología Lean puede aplicarse de manera efectiva a un servicio de urología de un hospital terciario para mejorar la eficiencia, obteniéndose una mejora importante y continua de todos sus indicadores, y de la satisfacción de sus profesionales. La formación de equipo, la gestión por procesos, la mejora continua y la delegación de responsabilidades se muestran como pilares fundamentales en dicha metodología

Objective: To describe the application of the Lean methodology as a method for continuously improving the efficiency of a urology department in a tertiary hospital. Material and methods: The implementation of the Lean Healthcare methodology in a urology department was conducted in 3 phases: 1) team training and improvement of feedback among the practitioners, 2) management by process and superspecialisation and 3) improvement of indicators (continuous improvement). The indicators were obtained from the Hospital's information systems. The main source of information was the Balanced Scorecard for health systems management (CUIDISS). The comparison with other autonomous and national urology departments was performed through the same platform with the help of the Hospital's records department (IASIST). A baseline was established with the indicators obtained in 2011 for the comparative analysis of the results after implementing the Lean Healthcare methodology. Results: The implementation of this methodology translated into high practitioner satisfaction, improved quality indicators reaching a risk-adjusted complication index (RACI) of 0.59 and a risk-adjusted mortality rate (RAMR) of 0.24 in 4 years. A value of 0.61 was reached with the efficiency indicator (risk-adjusted length of stay [RALOS] index), with a savings of 2869 stays compared with national Benchmarking (IASIST). The risk-adjusted readmissions index (RARI) was the only indicator above the standard, with a value of 1.36 but with progressive annual improvement of the same. Conclusions: The Lean methodology can be effectively applied to a urology department of a tertiary hospital to improve efficiency, obtaining significant and continuous improvements in all its indicators, as well as practitioner satisfaction. Team training, management by process, continuous improvement and delegation of responsibilities has been shown to be the fundamental pillars of this methodology

Application of Lean Healthcare methodology in a urology department of a tertiary hospital as a tool for improving efficiency. / Aplicación de la metodología Lean healthcare en un servicio de urología de un hospital terciario como herramienta de mejora de la eficiencia.

OBJECTIVE: To describe the application of the Lean methodology as a method for continuously improving the efficiency of a urology department in a tertiary hospital. MATERIAL AND METHODS: The implementation of the Lean Healthcare methodology in a urology department was conducted in 3 phases: 1) team training and improvement of feedback among the practitioners, 2) management by process and superspecialisation and 3) improvement of indicators (continuous improvement). The indicators were obtained from the Hospital's information systems. The main source of information was the Balanced Scorecard for health systems management (CUIDISS). The comparison with other autonomous and national urology departments was performed through the same platform with the help of the Hospital's records department (IASIST). A baseline was established with the indicators obtained in 2011 for the comparative analysis of the results after implementing the Lean Healthcare methodology. RESULTS: The implementation of this methodology translated into high practitioner satisfaction, improved quality indicators reaching a risk-adjusted complication index (RACI) of 0.59 and a risk-adjusted mortality rate (RAMR) of 0.24 in 4 years. A value of 0.61 was reached with the efficiency indicator (risk-adjusted length of stay [RALOS] index), with a savings of 2869 stays compared with national Benchmarking (IASIST). The risk-adjusted readmissions index (RARI) was the only indicator above the standard, with a value of 1.36 but with progressive annual improvement of the same. CONCLUSIONS: The Lean methodology can be effectively applied to a urology department of a tertiary hospital to improve efficiency, obtaining significant and continuous improvements in all its indicators, as well as practitioner satisfaction. Team training, management by process, continuous improvement and delegation of responsibilities has been shown to be the fundamental pillars of this methodology.

Costes y procesos hospitalarios en un servicio de urología de un hospital terciario. Análisis de los grupos relacionados por el diagnóstico / Costs and hospital procedures in an urology department of a tertiary hospital. Analysis of groups related by their diagnosis

Introducción: El sistema sanitario tiene disponibles herramientas de gestión en los hospitales que facilitan la valoración de la eficiencia mediante el estudio de los costes y el control de gestión con la finalidad de sacar un mayor provecho de los recursos. Objetivo: El objetivo del estudio ha sido el cálculo y análisis del coste total de un servicio de urología de un hospital terciario, tanto de la actividad ambulatoria como de hospitalización y quirúrgica, así como la realización de una cuenta de resultados donde se compararon los costes del servicio con los ingresos obtenidos a partir de la Ley de Tasas durante el año 2014. Material y métodos: A partir de la información registrada por el Sistema de Información Económica de la Consellería de Sanidad, se aplicó el método ABC y top-down para el cálculo de costes por proceso de la actividad asistencial de 2014. Los resultados de costes obtenidos se compararon con las tarifas establecidas para la producción ambulatoria y hospitalaria en la Ley de Tasas de la Generalitat Valenciana. La producción se estructuró en ambulatoria (consultas externas y técnicas) y hospitalaria (estancias e intervenciones quirúrgicas). Resultados: Se realizaron 32.510 consultas externas, 7.527 técnicas, 2.860 intervenciones y 4.855 estancias hospitalarias. El coste total fue de 7.579.327 € consultas externas 1.748.14 5 €, consultas técnicas 1.229.836 €, cirugía 2.621.036 € e ingresos hospitalarios 1.980.310 €. Considerándose como ingresos económicos las tarifas aplicadas vigentes el año 2014 (un total de 15.035.843 €), la diferencia entre ingresos y gastos fue de 7.456.516 €. Conclusiones: La cuenta de resultados fue positiva, con un ahorro producido sobre las tasas cercano al 50% y mejor que el índice de estancias medias ajustadas por casuística, que fue de 0,67 (un 33% mejor que el estándar). El incremento de la cirugía mayor ambulatoria CMA repercute favorablemente en el control de costes

Introduction: The health care system has management tools available in hospitals that facilitate the assessment of efficiency through the study of costs and management control in order to make a better use of the resources. Objective: The aim of the study was the calculation and analysis of the total cost of a urology department, including ambulatory, hospitalization and surgery activity and the drafting of an income statement where service costs are compared with income earned from the Government fees during 2014. Material and methods: From the information recorded by the Economic Information System of the Department of Health, ABC and top-down method of cost calculation was applied by process care activity. The cost results obtained were compared with the rates established for ambulatory and hospital production in the Tax Law of the Generalitat Valenciana. The production was structured into outpatient (external and technical consultations) and hospital stays and surgeries (inpatient). Results: A total of 32,510 outpatient consultations, 7,527 techniques, 2,860 interventions and 4,855 hospital stays were made during 2014. The total cost was 7,579,327 €; the cost for outpatient consultations was 1,748,145 €, 1,229,836 € for technical consultations, 2,621,036 € for surgery procedures and 1,980,310 € for hospital admissions. Considered as income the current rates applied in 2014 (a total of 15,035,843 Euros), the difference between income and expenditure was 7,456,516 Euros. Conclusions: The economic balance was positive with savings over 50% and a mean adjusted hospitalization stay rate (IEMAC) rate of 0.67 (33% better than the standard). CMA had a favorable impact on cost control

Papel del IGF-1 y la distribución de la grasa corporal para disminuir el número de rebiopsias prostáticas / The role of IGF-1 and the distribution of body fat in decreasing the number of prostate rebiopsies

Objetivo: Valorar la utilidad del IGF-1 y la grasa en órganos internos medida por impedanciometría bioeléctrica para el ahorro de rebiopsias innecesarias en pacientes con persistencia de PSA elevado. Material y método: Estudio prospectivo en 92 pacientes sometidos a rebiopsia de próstata por PSA elevado con tacto rectal negativo y ausencia de lesiones preneoplásicas. Previamente se determinó el valor de IGF-1 y se realizó un test de impedanciometría mediante el sistema abdominal Fat Analyser AB-140 TANITA. Se calcularon las curvas ROC para el PSA, % PSA, grasa en órganos internos e IGF-1 y PSA densidad. Resultados: Veinticinco pacientes fueron diagnosticados de cáncer de próstata. Estos presentaron de forma significativa mayores valores de PSA, PSAd e IGF-1 y una tendencia a mayores valores de grasa en órganos internos y menores cifras de %PSA (p = 0,001; p = 0,003; p = 0,001; p = 0,24 y p = 0,28 respectivamente). La curva ROC mostró un área bajo la curva del IGF-1 y del PSA de 0,82 y 0,81. Empleando los puntos de corte para la sensibilidad del 95% y usando los 3 criterios como indicación de rebiopsia se habría ahorrado un 74% de las biopsias dejando de diagnosticar únicamente a un paciente con cáncer clínicamente significativo ->Gleason 7(4 + 3)-. Los valores predictivos positivo y negativo para el conjunto de las variables fue superior a las de cada una por separado (VPP: 66/VPN: 63). El coste de ambas determinaciones es de 82 euros. Conclusiones: Nuestros resultados sugieren que la medición de IGF-1 podría disminuir el número de rebiopsias innecesarias de forma significativa, barata e inocua

Objective: To assess the usefulness of IGF-1 and internal organ fat measured by bioelectrical impedance audiometry to avoid rebiopsies in patients with persistently high prostate-specific antigen (PSA) levels. Material and method: A prospective study was conducted with 92 patients who underwent prostate rebiopsy due to high PSA levels with negative results in the rectal examination and a lack of preneoplastic lesions. The patients previously had their IGF-1 levels measured and had undergone an impedance audiometry test using the abdominal Fat Analyser AB-140 TANITA system. We calculated the receiver operating characteristic (ROC) curves for the PSA levels, %PSA, internal organ fat and IGF-1 and PSA density. Results: Twenty-five patients were diagnosed with prostate cancer. These patients had significantly higher PSA, PSAd and IGF-1 values and a tendency towards higher internal organ fat levels and lower %PSA readings (p = .001, p = .003, p = .001, p = .24 and P = 0.28, respectively). The ROC curve showed an area under the curve for IGF-1 and PSA of .82 and .81, respectively. Using the cutoff points for 95% sensitivity and using the 3 criteria as an indication of rebiopsy, 74% of the biopsies would have been spared, leaving undiagnosed only 1 patient with clinically significant cancer -Gleason score > 7 (4+3)-. The positive and negative predictive values for the set of variables were higher than for each one separately (PPV: 66/NPV: 63). The cost of both determinations was 82 euros. Conclusions: Our results suggest that measuring IGF-1 could significantly decrease the number of unnecessary rebiopsies in an inexpensive and safe manner

Costs and hospital procedures in an urology department of a tertiary hospital. Analysis of groups related by their diagnosis. / Costes y procesos hospitalarios en un servicio de urología de un hospital terciario. Análisis de los grupos relacionados por el diagnóstico.

INTRODUCTION: The health care system has management tools available in hospitals that facilitate the assessment of efficiency through the study of costs and management control in order to make a better use of the resources. OBJECTIVE: The aim of the study was the calculation and analysis of the total cost of a urology department, including ambulatory, hospitalization and surgery activity and the drafting of an income statement where service costs are compared with income earned from the Government fees during 2014. MATERIAL AND METHODS: From the information recorded by the Economic Information System of the Department of Health, ABC and top-down method of cost calculation was applied by process care activity. The cost results obtained were compared with the rates established for ambulatory and hospital production in the Tax Law of the Generalitat Valenciana. The production was structured into outpatient (external and technical consultations) and hospital stays and surgeries (inpatient). RESULTS: A total of 32,510 outpatient consultations, 7,527 techniques, 2,860 interventions and 4,855 hospital stays were made during 2014. The total cost was 7,579,327€; the cost for outpatient consultations was 1,748,145€, 1,229,836 Euros for technical consultations, 2,621,036€ for surgery procedures and 1,980,310€ for hospital admissions. Considered as income the current rates applied in 2014 (a total of 15,035,843€), the difference between income and expenditure was 7,456,516€. CONCLUSIONS: The economic balance was positive with savings over 50% and a mean adjusted hospitalization stay rate (IEMAC) rate of 0.67 (33% better than the standard). CMA had a favorable impact on cost control.

The role of IGF-1 and the distribution of body fat in decreasing the number of prostate rebiopsies. / Papel del IGF-1 y la distribución de la grasa corporal para disminuir el número de rebiopsias prostáticas.

OBJECTIVE: To assess the usefulness of IGF-1 and internal organ fat measured by bioelectrical impedance audiometry to avoid rebiopsies in patients with persistently high prostate-specific antigen (PSA) levels. MATERIAL AND METHOD: A prospective study was conducted with 92 patients who underwent prostate rebiopsy due to high PSA levels with negative results in the rectal examination and a lack of preneoplastic lesions. The patients previously had their IGF-1 levels measured and had undergone an impedance audiometry test using the abdominal Fat Analyser AB-140 TANITA system. We calculated the receiver operating characteristic (ROC) curves for the PSA levels, %PSA, internal organ fat and IGF-1 and PSA density. RESULTS: Twenty-five patients were diagnosed with prostate cancer. These patients had significantly higher PSA, PSAd and IGF-1 values and a tendency towards higher internal organ fat levels and lower %PSA readings (p=.001, p=.003, p=.001, p=.24 and P=0.28, respectively). The ROC curve showed an area under the curve for IGF-1 and PSA of .82 and .81, respectively. Using the cutoff points for 95% sensitivity and using the 3 criteria as an indication of rebiopsy, 74% of the biopsies would have been spared, leaving undiagnosed only 1 patient with clinically significant cancer -Gleason score>7 (4+3)-. The positive and negative predictive values for the set of variables were higher than for each one separately (PPV: 66/NPV: 63). The cost of both determinations was 82 euros. CONCLUSIONS: Our results suggest that measuring IGF-1 could significantly decrease the number of unnecessary rebiopsies in an inexpensive and safe manner.

Estudio multicéntrico de costes de 2 técnicas quirúrgicas: láser GreenLight XPS 180 W vs resección transuretral de la próstata / Multicenter Study on Costs Associated With Two Surgical Procedures: GreenLight XPS 180 W Versus the Gold Standard Transurethral Resection of the Prostate

Objetivo: Analizar los costes asociados al tratamiento quirúrgico de la sintomatología del tracto urinario inferior secundaria a hiperplasia benigna de próstata mediante el láser GreenLigh XPS 180 W respecto a la técnica quirúrgica endoscópica de referencia, resección transuretral de la próstata. Métodos: Se realizó un estudio retrospectivo y multicéntrico de costes desde la perspectiva del Sistema Nacional de Salud y en un horizonte temporal de 3 meses, desagregándolos en fases temporales: prequirúrgica, quirúrgica y posquirúrgica. Los datos fueron extraídos de las historias de los pacientes intervenidos secuencialmente, con IPSS = 15, Qmax = 15 ml/seg y volumen prostático de 40-80 ml, incorporando solo costes sanitarios directos (euros de 2013) asociados a la intervención y al manejo de complicaciones. Resultados: Entre julio y octubre de 2012 se intervinieron de forma secuencial 39 pacientes con láser GL XPS y 40 con RTUP. El resultado clínico fue equivalente (94,9 y 92,5%, respectivamente) no mostrando diferencias estadísticamente significativas (p = 0,67). El coste medio total por paciente se redujo en 121 Euros en el grupo láser GL XPS respecto de RTUP; en la fase quirúrgica el coste fue superior con láser GL XPS (diferencia: 1.209 Euros; p < 0,001) mientras que fue inferior en la fase posquirúrgica (diferencia: -1.351 Euros, p < 0,001). Conclusiones: La intervención de los pacientes con STUI secundario a HBP mediante la nueva tecnología láser GL XPS se asocia a una reducción de costes respecto de la RTUP, debida a una menor duración de la estancia hospitalaria, la cual compensa el coste imputado a dicha tecnología

Objective: To analyze the costs associated with two surgical procedures for lower urinary tract symptoms secondary to benign prostatic hyperplasia: GreenLight XPS 180 W versus the gold standard transurethral resection of the prostate. Methods: A multicenter, retrospective cost study was carried out from the National Health Service perspective, over a 3-month time period. Costs were broken down into pre-surgical, surgical and post-surgical phases. Data were extracted from records of patients operated sequentially, with IPSS = 15, Qmax = 15 mL/seg and a prostate volume of 40–80 mL, adding only direct healthcare costs (Euros, 2013) associated with the procedure and management of complications. Results: A total of 79 patients sequentially underwent GL XPS (n: 39) or TURP (n: 40) between July and October 2013. Clinical outcomes were similar (94.9% and 92.5%, GL XPS and TURP, respectively) without significant differences (p = 0.67). The average direct cost per patient was reduced by 114Euros in GL XPS versus TURP patients; the cost was higher in the surgical phase with GL XPS (difference: 1209Euros; p < 0.001) but was lower in the post-surgical phase (difference: Euros − 1351; p < 0.001). Conclusions: The GreenLight XPS 180-W laser system is associated with a reduction in costs with respect to transurethral resection of prostate in the surgical treatment of LUTS secondary to PBH. This reduction is due to a shorter inpatient length of stay that offsets the cost of the new technology

Réplica a "Fitoterapia en Urología. Evidencia científica actual de su aplicación en hiperplasia benigna de próstata y adenocarcinoma de próstata" / Reply to "Phytotherapy in Urology. Current Scientific Evidence of its Application in Benign Prostatic Hyperplasia and Prostate Adenocarcinoma"

No disponible

Multicenter study on costs associated with two surgical procedures: GreenLight XPS 180 W versus the gold standard transurethral resection of the prostate.

OBJECTIVE: To analyze the costs associated with two surgical procedures for lower urinary tract symptoms secondary to benign prostatic hyperplasia: GreenLight XPS 180¦W versus the gold standard transurethral resection of the prostate. METHODS: A multicenter, retrospective cost study was carried out from the National Health Service perspective, over a 3-month time period. Costs were broken down into pre-surgical, surgical and post-surgical phases. Data were extracted from records of patients operated sequentially, with IPSS=15, Qmax=15 mL/seg and a prostate volume of 40-80mL, adding only direct healthcare costs (€, 2013) associated with the procedure and management of complications. RESULTS: A total of 79 patients sequentially underwent GL XPS (n: 39) or TURP (n: 40) between July and October, 2013. Clinical outcomes were similar (94.9% and 92.5%, GL XPS and TURP, respectively) without significant differences (P=.67). The average direct cost per patient was reduced by €114 in GL XPS versus TURP patients; the cost was higher in the surgical phase with GL XPS (difference: €1,209; P<.001) but was lower in the post-surgical phase (difference: €-1,351; P<.001). CONCLUSIONS: The GreenLight XPS 180-W laser system is associated with a reduction in costs with respect to transurethral resection of prostate in the surgical treatment of LUTS secondary to PBH. This reduction is due to a shorter inpatient length of stay that offsets the cost of the new technology.

Fitoterapia en Urología. Evidencia científica actual de su aplicación en urolitiasis, dolor pélvico crónico, disfunción eréctil e infecciones urinarias / Phytotherapy in Urology. Current Scientific Evidence of its Application in Urolithiasis, Chronic Pelvic Pain, Erectile Dysfunction and Urinary Tract Infections

Objetivo: Evaluar la utilidad de la fitoterapia en urolitiasis, infecciones urinarias, disfunción eréctil (DE) y prostatitis crónica/dolor pélvico crónico (PC/DPC). Adquisición de la evidencia: Revisión sistemática de la evidencia publicada hasta enero del 2011 empleando los términos científicos: fitoterapia, litiasis urinaria, prostatitis crónica, dolor pélvico crónico, disfunción eréctil, infección urinaria, cistitis y los nombres científicos de los compuestos siguiendo las normas del Código Internacional de Nomenclatura Botánica. Las bases de datos utilizadas fueron Medline y The Cochrane Library. Se incluyeron artículos publicados hasta enero del 2011 en español/inglés. Se incluyeron estudios in vitro/in vivo sobre modelos animales o seres humanos. Los criterios de exclusión fueron literatura no española/inglesa o artículos con graves defectos metodológicos. Síntesis de la evidencia: Se incluyeron 86 artículos y se seleccionaron 40 que cumplieron los criterios de inclusión. En urolitiasis hay pocos trabajos en humanos. El fitato tiene su principal utilidad como prevención y en la disminución del crecimiento de fragmentos residuales tras litotricia extracorpórea por ondas de choque (LEOCH). En PC/DPC el único compuesto que ha demostrado eficacia fue el extracto de polen en un ámbito de tratamiento multimodal. En DE no hay evidencia a favor del uso de la fitoterapia. La mayoría de los trabajos presentan limitaciones en el diseño o escaso tamaño muestral. En infecciones urinarias la mayoría de los productos son diuréticos. Solo existe evidencia para el arándano rojo como prevención en mujeres jóvenes o embarazadas. No debe emplearse como tratamiento de las infecciones urinarias. Conclusiones: La fitoterapia muestra utilidad en las infecciones urinarias de repetición y en la PC/DPC. Tiene cierto papel en la urolitiasis y carece de utilidad en la DE (AU)

Objective: To assess the usefulness of phytotherapy in urolitiasis, urinary tract infections, erectile dysfunction (ED) and chronic prostatitis/chronic pelvic pain (CP/CPP). Acquisition of the evidence: Systematic review of the evidence published until January 2011 using the following scientific terms: phytotherapy, urinary lithiasis, Chronic prostatitis, chronic pelvic pain, erectile dysfunction, urinary tract infection, cystitis and the scientific names of compounds following the rules of the International Code of Botanical Nomenclature. The databases used were Medline and The Cochrane Library. We included articles published until January 2011 written in English and Spanish. We included studies in Vitro/in vivo on animal models or human beings. Exclusion criteria were literature not in English and Spanish or articles with serious methodological flaws. Synthesis of the evidence: We included 86 articles selecting 40 that met the inclusion criteria. In Urolitiasis there are few works in humans. The phytate has its main use as prevention and in reducing the growth of residual fragments after extracorporeal shock wave lithotripsy (ESWL). In CP/CPP the only compound that has shown effectiveness was the extract of pollen in a field of multimodal treatment. In DE ther is no evidence for the use of herbal medicine. Most of the works have limitations in the design or low sample size. In urinary tract infections most of the products are diuretics .There is only evidence for the cranberry as prevention in young or pregnant women. It must not be used as a treatment for urinary tract infections. Conclusions: Phytotherapy is usefull in repeat urinary tract infections and the CP/CPP. It has some role in the urolitiasis and lacks useful in the DE (AU)

Fitoterapia en Urología. Evidencia científica actual de su aplicación en hiperplasia benigna de próstata y adenocarcinoma de próstata / Phytotherapy in Urology. Current Scientific Evidence of its Application in Benign Prostatic Hyperplasia and Prostate Adenocarcinoma

Objetivo: Evaluar la utilidad de la fitoterapia en el tratamiento de la hiperplasia benigna de próstata (HBP) y el adenocarcinoma prostático (ADCP). Adquisición de la evidencia: Se realizó una revisión sistemática de la evidencia publicada hasta enero del 2011, empleando los términos científicos fitoterapia, hiperplasia benigna de próstata, adenocarcinoma prostático, cáncer de próstata, y los nombres científicos de los compuestos siguiendo las normas del Código Internacional de Nomenclatura Botánica. Las bases de datos utilizadas fueron Medline y The Cochrane Library. Se incluyeron artículos publicados hasta enero del 2011, escritos en español e inglés. Se incluyeron estudios in vitro/in vivo sobre modelos animales o seres humanos. Los criterios de exclusión fueron literatura no española/inglesa o artículos con graves defectos metodológicos. Síntesis de la evidencia: Se incluyeron 65 artículos, de los cuales se seleccionaron 40 que cumplieron los criterios de inclusión. HBP: los productos más estudiados son la Serenoa repens y Pygeum africanum. Existen muchos estudios a favor del empleo de la fitoterapia; no obstante, sus conclusiones son poco consistentes debido al escaso número de pacientes, la falta de control con placebo o el escaso seguimiento. A pesar de ello el empleo de estos productos es habitual en nuestro medio. ADCP: no existe evidencia para recomendar la fitoterapia en el tratamiento del ADCP. Existen trabajos respecto de la prevención, aunque únicamente a nivel experimental, por lo que tampoco existe evidencia para su recomendación. Conclusiones: La evidencia científica acerca del empleo de la fitoterapia en la afección prostática es concluyente a la hora de no recomendarla en el empleo de la HBP o el ADCP (AU)

Objective: To evaluate the usefulness of phytotherapy in the treatment of the benign prostatic hyperplasia (BPH) and prostatic adenocarcinoma (ADCP). Acquisition of evidence: Systematic review of the evidence published until January 2011 using the following scientific terms: phytotherapy, benign prostate hyperplasia, prostatic adenocarcinoma, prostate cancer and the scientific names of compounds following the rules of the International Code of Botanical Nomenclature. The databases used were Medline and The Cochrane Library. We included articles published until January 2011 written in English and Spanish. We included studies in vitro/in vivo on animal models or human beings. Exclusion criteria were literature not in English and Spanish or articles with serious methodological flaws. Synthesis of the evidence: We included 65 articles of which 40 met the inclusion criteria. BPH: the most studied products are serenoa repens and pygeum africanum. There are many studies in favour of the use of phytotherapy but its conclusions are inconsistent due to the small number of patients, the lack of control with placebo or short follow-up. However the use of these products is common in our environment. ADCP: there is no evidence to recommend phytotherapy in the treatment of the ADCP. There are works on prevention but only at experimental level so there is no evidence for its recommendation. Conclusions: The scientific evidence on the use of phytotherapy in prostatic pathology is conclusive not recommend ing the use of it for BPH or the ADCP (AU)

[Phytotherapy in urology. Current scientific evidence of its application in urolithiasis, chronic pelvic pain, erectile dysfunction and urinary tract infections]. / Fitoterapia en Urología. Evidencia científica actual de su aplicación en urolitiasis, dolor pélvico crónico, disfunción eréctil e infecciones urinarias.

OBJECTIVE: To assess the usefulness of phytotherapy in urolitiasis, urinary tract infections, erectile dysfunction (ED) and chronic prostatitis/chronic pelvic pain (CP/CPP). ACQUISITION OF THE EVIDENCE: Systematic review of the evidence published until January 2011 using the following scientific terms:phytotherapy, urinary lithiasis, Chronic prostatitis, chronic pelvic pain, erectile dysfunction, urinary tract infection, cystitis and the scientific names of compounds following the rules of the International Code of Botanical Nomenclature. The databases used were Medline and The Cochrane Library.We included articles published until January 2011 written in English and Spanish. We included studies in Vitro/in vivo on animal models or human beings. Exclusion criteria were literature not in English and Spanish or articles with serious methodological flaws. SYNTHESIS OF THE EVIDENCE: We included 86 articles selecting 40 that met the inclusion criteria. In Urolitiasis there are few works in humans. The phytate has its main use as prevention and in reducing the growth of residual fragments after extracorporeal shock wave lithotripsy (ESWL). In CP/CPP the only compound that has shown effectiveness was the extract of pollen in a field of multimodal treatment. In DE ther is no evidence for the use of herbal medicine.Most of the works have limitations in the design or low sample size. In urinary tract infections most of the products are diuretics .There is only evidence for the cranberry as prevention in young or pregnant women. It must not be used as a treatment for urinary tract infections. CONCLUSIONS: Phytotherapy is usefull in repeat urinary tract infections and the CP/CPP. It has some role in the urolitiasis and lacks useful in the DE.

[Phytotherapy in urology. Current scientific evidence of its application in benign prostatic hyperplasia and prostate adenocarcinoma]. / Fitoterapia en Urología. Evidencia científica actual de su aplicación en hiperplasia benigna de próstata y adenocarcinoma de próstata.

OBJECTIVE: To evaluate the usefulness of phytotherapy in the treatment of the benign prostatic hyperplasia (BPH) and prostatic adenocarcinoma (ADCP). ACQUISITION OF EVIDENCE: Systematic review of the evidence published until January 2011 using the following scientific terms: phytotherapy, benign prostate hyperplasia, prostatic adenocarcinoma, prostate cancer and the scientific names of compounds following the rules of the International Code of Botanical Nomenclature. The databases used were Medline and The Cochrane Library. We included articles published until January 2011 written in English and Spanish. We included studies in vitro/in vivo on animal models or human beings. Exclusion criteria were literature not in English and Spanish or articles with serious methodological flaws. SYNTHESIS OF THE EVIDENCE: We included 65 articles of which 40 met the inclusion criteria. BPH: the most studied products are serenoa repens and pygeum africanum. There are many studies in favour of the use of phytotherapy but its conclusions are inconsistent due to the small number of patients, the lack of control with placebo or short follow-up. However the use of these products is common in our environment. ADCP: there is no evidence to recommend phytotherapy in the treatment of the ADCP. There are works on prevention but only at experimental level so there is no evidence for its recommendation. CONCLUSIONS: The scientific evidence on the use of phytotherapy in prostatic pathology is conclusive not recommend ing the use of it for BPH or the ADCP.

Utilidad de los nuevos esquemas de agrupación de los grados de Fuhrman en la práctica clínica para el tumor renal de células claras / Usefulness of New Schemes to Group Fuhrman Grades in Clinical Practice for Clear Cell Renal Tumour

Objetivo: Evaluar si la re-clasificación de los carcinomas renales de células claras (CRCC) en dos o tres grados de Fuhrman (GF) frente a la clasificación clásica mantiene su valor pronóstico. Material y métodos: Estudio sobre una cohorte de 383 CRCC tratados con nefrectomía radical/parcial (1990-2009). Se analizaron datos demográficos, evolución y supervivencia de los pacientes. Un uropatólogo reasignó los grados de Fuhrman de forma ciega al informe original. Para estudiar si se mantenía el valor pronóstico con las distintas clasificaciones se realizaron tres análisis de regresión múltiple de Cox, categorizando la variable grado en 4 categorías (I-II-III-IV), en tres (I+II-III-IV) y en dos (I+II-III+IV). Las variables explicativas fueron: edad, sexo, tamaño tumoral, estadio y grado. Las variables respuesta fueron: tiempo de supervivencia libre de progresión (recidiva locorregional /metástasis) y de supervivencia cáncer-específica. Resultados: La mediana de supervivencia global fue de 125 meses (IC 95%: 92-159). En los tres análisis multivariantes el grado de Fuhrman demostró valor predictivo independiente (p=0,0001) frente al estadio para la supervivencia libre de progresión y supervivencia cáncer-específica. El valor pronóstico se mantuvo en las nuevas clasificaciones. En la de tres categorías el paso del grado I+II al III presentó un RR: 2,31(p=0,0001) y del grado III al IV un RR: 2,47(p=0,0001) y en la de dos categorías se observó un RR: 2,8 (p=0,001) al pasar del grado I+II al III+IV. Conclusiones: La categorización en dos o tres grupos del grado de Fuhrman mantiene la capacidad predictiva sobre la supervivencia libre de progresión y cáncer-específica. Los grados III y IV presentan evoluciones distintas, por lo que la clasificación en tres categorías parece más adecuada para describir la evolución de estos pacientes (AU)

Objective: To evaluate if re-grading renal cell carcinoma (CRCC) in two or three-tiered grading schemes versus the traditional Fuhrman classification maintains the same prognostic value. Material and methods: A study of a cohort of 383 treated CRCC with radical or partial nephrectomy between 1990-2009 was made. We analyzed the demographic data, evolution and survival of these patients. An uropathologist reassigned the Fuhrman grades blindly to the first classification. In order to study if the prognostic value was maintained with the different classification, three Cox multivariate regression analysis were performed, classifying the variable of grade into four categories: (I-II-III-IV), into three (I+II-III-IV) and into two (I+II-III+IV). The explanatory variables were: age, gender, tumor size, study stage and grade. The response variables were progression-free survival (local-regional recurrence/metastasis) and cancer specific survival time. Results: The median overall survival was 125 months (95% CI: 92-159). In the three multivariate analyses carried out, the Fuhrman classification showed independent predictive value (p=:0.0001) compared to progression-free survival and cancer specific survival. The predictive power was maintained in the new classifications. In the three categories, the changing from grade I+II to III meant RR: 2.31 (p=0.0001) and from grade III to IV RR: 2.47 (p=0.0001) and in two-tiered classification an RR: 2.8 (p=0.001) was found when changing from I+II to III+IV. Conclusions: Our results show that categorizing the Fuhrman grade into three or two-tiered grading schemes provide the same predictive accuracy on progressive free survival and cancer specific survival. Grades III and IV have different outcomes so that the three-tiered classification seems to be more appropriate to described the course of these patients (AU)

Prognostic nomogram for disease-free survival in patients with renal adenocarcinoma.

OBJECTIVE: The aim of this study was to develop a postoperative prognostic nomogram for disease-free survival in patients with renal adenocarcinoma. MATERIALS AND METHODS: A total of 224 patients with organ-confined or locally advanced renal adenocarcinoma were treated with radical or partial nephrectomy. The variables included in the model were age, histological type, pathological stage, Fuhrman grade and DNA ploidy. Tumor recurrence was defined as any clinical evidence of recurrence. The probability of progression-free survival was calculated using the Kaplan-Meier estimate, and multivariate analysis was performed using a Cox regression. The nomogram was created using the data obtained from the Cox regression. RESULTS: Tumor recurrence was detected in 89 patients (39.74%). The median progression-free time in these patients was 9.55 months (range 0-133). Of these patients, 70.9% relapsed during the first 2 years, and only 15 patients (6.9%) were alive but ill at the end of the study. The probability of progression-free survival at 5 and 10 years was 66.64 and 61.97%, respectively. We performed a statistical validation of the model with accurate predictions that were discriminated with a confidence interval of 0.75 (comparing the predicted and actual probability). According to the nomogram obtained, patients with low-grade, diploid, organ-confined tumors would be candidates for follow-up not exceeding 5 years due to the low probability of recurrence (<40 points). CONCLUSION: The nomogram we developed is clinically relevant and can provide prognostic information for both patients and researchers. In addition, it can be used by researchers during the monitoring protocols that categorize patients based on their relative risk of disease progression.